Modality
Bispecific Ab
MOA
BiTE
Target
CD19
Pathway
Hedgehog
PsA
Development Pipeline
Preclinical
~Feb 2023
→ ~May 2024
Phase 1
Aug 2024
Phase 1Current
NCT06884878
460 pts·PsA
2024-08→TBD·Not yet recruiting
460 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P1/2
Not yet…
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06884878 | Phase 1/2 | PsA | Not yet recr... | 460 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| BII-8315 | Biogen | NDA/BLA | CDK2 | |
| Geliglumide | Samsung Biologics | Phase 1 | Aβ | |
| AXS-4984 | Axsome | Preclinical | JAK2 |